Author

Marla C. Dubinsky 1

1 Icahn School of Medicine at Mount Sinai,New York,United States

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Marla C. Dubinsky

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Marla C. Dubinsky, Remo Panaccione, James D Lewis, Bruce E. Sands, Toshifumi Hibi, Scott D. Lee, April Naegeli, Mingyang Shan, Linden Green, Nathan Morris, Vipin Arora, Alison Potts Bleakman, Ruth Belin, Simon Travis

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Marla C. Dubinsky, Scott D. Lee, Remo Panaccione, Maria T. Abreu, Severine Vermeire, Trevor Lissoos, Nathan Morris, Vipin Arora, Mingyang Shan, April Naegeli, Bruce E. Sands

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Marla C. Dubinsky

BURDEN OF DISEASE IN PAEDIATRIC PATIENTS WITH MODERATE VERSUS SEVERE CROHN’S DISEASE IN THE IMAGINE 1 TRIAL

Frank Ruemmele, Jeffrey S Hyams, Joel Rosh, Marla C. Dubinsky, James Markowitz, Anne Griffiths, Dan Turner, Samantha Eichner, Andreas Lazar, Anne M. Robinson, Bidan Huang, Roopal B Thakkar

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

Julian Panés, Jean-Frederic Colombel, Severine Vermeire, Marla C. Dubinsky, Ala I. Sharara, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Edward V. Loftus Jr.

Faecal calprotectin levels, C-reactive protein levels and partial Mayo score as early predictors of clinical and endoscopic outcomes in adult patients with moderately to severely active ulcerative colitis treated with tofacitinib in a Phase 2 study

Marla C. Dubinsky, David P. Hudesman, nicole kulisek, Leonardo Salese, Jerome Paulissen, Chinyu Su, Fernando Magro

Item-level improvements in inflammatory bowel disease questionnaire scores in patients with ulcerative colitis treated with tofacitinib induction therapy

Marla C. Dubinsky, Marco DiBonaventura, Haiyun Fan, Andrew G. Bushmakin, Joseph C. Cappelleri, Eric Maller, Andrew J. Thorpe, Leonardo Salese, Julian Panés

PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES

Uma Mahadevan, Daniel C. Baumgart, Marla C. Dubinsky, Nervin Lawendy, Gary S. Friedman, Gauree G. Konijeti, Hans Peter Gröchenig, Thomas V Jones, Amy Marren, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES: AN UPDATE AS OF FEBRUARY 2020

Uma Mahadevan, Daniel C. Baumgart, Marla C. Dubinsky, Jesús K Yamamoto-Furusho, Nervin Lawendy, Gauree G. Konijeti, Hans Peter Gröchenig, Thomas V Jones, nicole kulisek, Kenneth Kwok, Chinyu Su

Item 1 - 10 / 11
1
2